葛兰素史克Glaxosmithkline（GSK）2025年第四季度及全年投资者和分析师财报电话会议PPT「LSE」（英文版）（47页）.pdf

1、FY and Q4 2025 ResultsFY and Q4 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts4 February 20264 February 2026AgendaAgendaStrong 2025 performance,2026 prioritiesStrong 2025 performance,2026 prioritiesLuke Miels Performance:growt

2、h driversPerformance:growth driversNina Mojas and Deborah WaterhousePipeline progressPipeline progressTony WoodFY 2025 performance and 2026 guidanceFY 2025 performance and 2026 guidanceJulie BrownSummary and Q&ASummary and Q&ALuke Miels,Nina Mojas,Deborah Waterhouse,Tony Wood,Julie Brown and David R

3、edfern 2This presentation may contain forward-looking statements.Forward-looking statements give the Groups current expectations or forecasts of future events.An investor can identify these statements by the fact that they do not relate strictly to historical or current facts.They use words such as

4、anticipate,estimate,expect,intend,will,project,plan,believe,target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.In particular,these include statements relating to future actions,prospective products or product approvals,f

5、uture performance or results of current and anticipated products,sales efforts,expenses,the outcome of contingencies such as legal proceedings,dividend payments and financial results.Other than in accordance with its legal or regulatory obligations(including under the Market Abuse Regulations,UK Lis

6、ting Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority),the Group undertakes no obligation to update any forward-looking statements,whether as a result of new information,future events or otherwise.Investors should,however,consult any additional disclosures